Régions 3' non traduites : Questions médicales fréquentes
Nom anglais: 3' Untranslated Regions
Descriptor UI:D020413
Tree Number:G05.360.340.024.340.137.910.880
Termes MeSH sélectionnés :
Language
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions 3' non traduites : Questions médicales les plus fréquentes",
"headline": "Régions 3' non traduites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions 3' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions non traduites",
"url": "https://questionsmedicales.fr/mesh/D020506",
"about": {
"@type": "MedicalCondition",
"name": "Régions non traduites",
"code": {
"@type": "MedicalCode",
"code": "D020506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Éléments riches en AU",
"alternateName": "AU Rich Elements",
"url": "https://questionsmedicales.fr/mesh/D063307",
"about": {
"@type": "MedicalCondition",
"name": "Éléments riches en AU",
"code": {
"@type": "MedicalCode",
"code": "D063307",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910.880.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites",
"alternateName": "3' Untranslated Regions",
"code": {
"@type": "MedicalCode",
"code": "D020413",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fan Jiang",
"url": "https://questionsmedicales.fr/author/Fan%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Dong-Zhi Li",
"url": "https://questionsmedicales.fr/author/Dong-Zhi%20Li",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Kevin Struhl",
"url": "https://questionsmedicales.fr/author/Kevin%20Struhl",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Raffaella Liccardo",
"url": "https://questionsmedicales.fr/author/Raffaella%20Liccardo",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
},
{
"@type": "Person",
"name": "Marina De Rosa",
"url": "https://questionsmedicales.fr/author/Marina%20De%20Rosa",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Attitudes and Preferences Towards Screening for Dementia with a Focus on Ethnic Minority and Low Socio-Economic Groups: A Systematic Review of Research Studies Written in the English Language.",
"datePublished": "2024-07-18",
"url": "https://questionsmedicales.fr/article/39031361",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3233/JAD-240315"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.",
"datePublished": "2024-07-12",
"url": "https://questionsmedicales.fr/article/38995237",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14796694.2024.2362108"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functional neuroimaging and behavioral correlates of multisite tDCS as an add-on to language training in a person with post-stroke non-fluent aphasia: a year-long case study.",
"datePublished": "2024-05-03",
"url": "https://questionsmedicales.fr/article/38700140",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13554794.2024.2349327"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost, Usability, Credibility, Fairness, Accountability, Transparency, and Explainability Framework for Safe and Effective Large Language Models in Medical Education: Narrative Review and Qualitative Study.",
"datePublished": "2024-04-23",
"url": "https://questionsmedicales.fr/article/38875562",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/51834"
}
},
{
"@type": "ScholarlyArticle",
"name": "Project Building Bridges: A Framework for Preparing Highly Qualified Speech-Language Pathologists to Serve Culturally and Linguistically Diverse Students With Augmentative and Alternative Communication Needs.",
"datePublished": "2024-03-27",
"url": "https://questionsmedicales.fr/article/38536710",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2024_AJSLP-23-00257"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Régions non traduites",
"item": "https://questionsmedicales.fr/mesh/D020506"
},
{
"@type": "ListItem",
"position": 9,
"name": "Régions 3' non traduites",
"item": "https://questionsmedicales.fr/mesh/D020413"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions 3' non traduites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions 3' non traduites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions 3' non traduites",
"description": "Comment identifier les 3' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 3' UTR ?\nLes 3' UTR sont-ils visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 3' UTR ?\nQuel rôle jouent les 3' UTR dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions 3' non traduites",
"description": "Les 3' UTR sont-ils associés à des symptômes cliniques ?\nQuels symptômes peuvent résulter de mutations dans les 3' UTR ?\nLes 3' UTR affectent-ils la réponse aux traitements ?\nY a-t-il des symptômes spécifiques liés aux 3' UTR ?\nLes 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions 3' non traduites",
"description": "Peut-on prévenir les maladies liées aux 3' UTR ?\nQuels conseils pour réduire les risques liés aux 3' UTR ?\nLes antécédents familiaux influencent-ils la prévention ?\nY a-t-il des programmes de prévention pour les 3' UTR ?\nComment le mode de vie affecte-t-il les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions 3' non traduites",
"description": "Comment traiter les maladies liées aux 3' UTR ?\nLes thérapies ciblées affectent-elles les 3' UTR ?\nPeut-on modifier les 3' UTR pour traiter des maladies ?\nLes traitements peuvent-ils influencer les 3' UTR ?\nY a-t-il des médicaments ciblant les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions 3' non traduites",
"description": "Quelles complications peuvent survenir avec les 3' UTR ?\nLes 3' UTR sont-ils liés à des cancers ?\nComment les 3' UTR affectent-ils la santé ?\nLes complications des 3' UTR sont-elles héréditaires ?\nY a-t-il des complications neurologiques liées aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions 3' non traduites",
"description": "Quels facteurs de risque sont associés aux 3' UTR ?\nL'environnement influence-t-il les 3' UTR ?\nLes habitudes de vie impactent-elles les 3' UTR ?\nLes mutations dans les 3' UTR sont-elles fréquentes ?\nY a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Language&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les 3' UTR dans un gène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les 3' UTR peuvent être identifiés par séquençage d'ARN et analyses bioinformatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les 3' UTR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le RT-PCR et les analyses de microarrays pour évaluer l'expression."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils visibles sur des électrophorèses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les 3' UTR ne sont pas visibles directement sur les gels d'électrophorèse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les 3' UTR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les 3' UTR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les 3' UTR dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent influencer la stabilité de l'ARN et l'expression des gènes, affectant le diagnostic."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils associés à des symptômes cliniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, des anomalies dans les 3' UTR peuvent entraîner des symptômes par régulation génique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter de mutations dans les 3' UTR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations peuvent causer des maladies génétiques, entraînant divers symptômes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR affectent-ils la réponse aux traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la réponse aux traitements en modifiant l'expression des gènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés aux 3' UTR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont généralement liés à des maladies spécifiques, pas aux 3' UTR eux-mêmes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des syndromes génétiques peuvent être associés à des mutations dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux 3' UTR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Quels conseils pour réduire les risques liés aux 3' UTR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et se soumettre à des tests génétiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des programmes de prévention pour les 3' UTR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de sensibilisation et de dépistage génétique existent pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les 3' UTR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut influencer l'expression génique, y compris celle des 3' UTR."
}
},
{
"@type": "Question",
"name": "Comment traiter les maladies liées aux 3' UTR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la maladie sous-jacente, souvent par thérapies géniques ou médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées affectent-elles les 3' UTR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines thérapies ciblées peuvent moduler l'expression des gènes via les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les 3' UTR pour traiter des maladies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de modification des 3' UTR sont en recherche pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils influencer les 3' UTR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent affecter la régulation des 3' UTR et l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments ciblant les 3' UTR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, peu de médicaments ciblent spécifiquement les 3' UTR, mais la recherche progresse."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les 3' UTR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies génétiques et des troubles de l'expression génique."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils liés à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations dans les 3' UTR peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Comment les 3' UTR affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils régulent l'expression des gènes, et des anomalies peuvent entraîner des problèmes de santé."
}
},
{
"@type": "Question",
"name": "Les complications des 3' UTR sont-elles héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être héréditaires, selon les mutations présentes dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques liées aux 3' UTR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations dans les 3' UTR peuvent être associées à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux 3' UTR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des environnements spécifiques."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les 3' UTR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent affecter l'expression des gènes régulés par les 3' UTR."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie impactent-elles les 3' UTR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes de vie, comme le tabagisme, peuvent influencer l'expression des 3' UTR."
}
},
{
"@type": "Question",
"name": "Les mutations dans les 3' UTR sont-elles fréquentes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations dans les 3' UTR sont moins fréquentes que dans les régions codantes, mais significatives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent évaluer les risques associés aux mutations dans les 3' UTR."
}
}
]
}
]
}
Increased understanding of dementia risk-reduction and early detection of Alzheimer's disease and related disorders has spurred interest in the identification of risks for dementia, underlying putativ...
In this systematic review, we sought published studies since 2012 on attitudes and preferences of people with dementia, carers and the general public from ethnic minorities and low socio-economic grou...
This review was preregistered on PROSPERO (CRD42023384115) and followed PRISMA guidelines. Key search terms were entered into five databases. Articles were included if they focused on population or ri...
Seven studies reported perspectives of ethnic minorities regarding dementia screening; one study included people from low socio-economic groups. Results indicated that participants from ethnic minorit...
Although there seems to be high acceptability for screening in the studied groups, more research is necessary to explore the practical considerations for screening such as cultural and economic barrie...
This summary describes the results from the TALAPRO-2 research study (also known as a clinical trial). The TALAPRO-2 study tested the combination of two medicines called talazoparib plus enzalutamide....
Metastatic castration-resistant prostate cancer is a type of cancer that starts in the prostate and has spread to other parts of the body. Castration-resistant means that the cancer continues to grow ...
TALAPRO-2 looked at if combining talazoparib plus enzalutamide would increase the length of time patients lived before their cancer got worse or they died compared with a placebo plus enzalutamide. Re...
A total of 805 patients with metastatic castration-resistant prostate cancer took part in the study. Compared with patients who took a placebo plus enzalutamide, the group of patients who took talazop...
Mary, who experienced non-fluent aphasia as a result of an ischemic stroke, received 10 years of personalized language training (LT), resulting in transient enhancements in speech and comprehension. T...
The world has witnessed increased adoption of large language models (LLMs) in the last year. Although the products developed using LLMs have the potential to solve accessibility and efficiency problem...
The aim of this study was to identify and prioritize the enablers for developing successful LLMs for medical education. We further evaluated the relationships among these identified enablers....
A narrative review of the extant literature was first performed to identify the key enablers for LLM development. We additionally gathered the opinions of LLM users to determine the relative importanc...
The AHP demonstrated that the most important enabler for LLMs was credibility, with a priority weight of 0.37, followed by accountability (0.27642) and fairness (0.10572). In contrast, usability, with...
This study is the first to identify, prioritize, and analyze the relationships of enablers of effective LLMs for medical education. Based on the results of this study, we developed a comprehendible pr...
Project Building Bridges was funded by the U.S. Department of Education Office of Special Education Programs to address the shortage of speech-language pathologists qualified to serve students with co...
Fifty-seven graduate students completed the project. The scholars' curriculum consisted of two AAC courses, both on-campus and externship AAC clinical practicum experiences to provide services to mult...
Mixed-methods outcome measures consisted of four sets of pre- and postsurveys and qualitative feedback from exit interviews to assess changes in graduate student competencies. Significant differences ...
Project Building Bridges provides a framework for preparing highly qualified speech-language pathologists to serve culturally and linguistically diverse students who benefit from AAC as evidenced by p...
Introduction Recently, large-scale language models, such as ChatGPT (OpenAI, San Francisco, CA), have evolved. These models are designed to think and act like humans and possess a broad range of speci...
Extracting research of domain criteria (RDoC) from high-risk populations like those with post-traumatic stress disorder (PTSD) is crucial for positive mental health improvements and policy enhancement...
In our study, we created an NLP workflow to analyze electronic medical record (EMR) data, and identify and extract research of domain criteria using a pre-trained transformer-based natural language mo...
The sentence transformer model demonstrated superior F1 macro scores across all RDoC domains, achieving the highest performance with a cosine similarity threshold value of 0.3. This ensured an F1 scor...
The findings provide initial insights into RDoC functioning in different populations and disease trajectories. Natural language processing proves valuable for capturing real-time, context dependent RD...
The Vaccine Adverse Event Reporting System (VAERS) has already been challenged by an extreme increase in the number of individual case safety reports (ICSRs) after the market introduction of coronavir...
The objective of this study was to develop a natural language processing (NLP)-based approach to optimize signal management by excluding disproportionality signals related to listed adverse events fol...
The VAERS was used as a data source, and the Finding Associated Concepts with Text Analysis (FACTA+) was used to extract signs and symptoms of listed AEFIs from MEDLINE for COVID-19 vaccines. Dispropo...
Overall, 17% of disproportionality signals for COVID-19 vaccines were dismissed as they reported signs and symptoms of listed AEFIs. Eight of nine NLP techniques used to automatically retrieve MedDRA ...
Our approach reduced the need for manual exclusion of disproportionality signals related to listed AEFIs and may lead to better optimization of time and resources in signal management....
Individuals with special needs requiring special care are more vulnerable to oral health problems. Sign language is a communication medium and language of instruction for individuals with hearing impa...
PubMed, Scopus, Embase, and Cochrane Central Register of Controlled Trials databases were searched without any restriction on the publication date. Analytical and experimental studies that evaluated a...
Initially, 5568 records were identified. Three relevant publications from India were eligible and included in the systematic review and meta-analysis. Differences were reported in favour of sign langu...
Sign language-based interventions were found to be effective. However, further studies in different locations and populations are required to support their effectiveness....